Heart failure biomarkers in patients with dilated cardiomyopathy

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2404-2410

  Bielecka Dabrowa, Agata ^a   Von Haehling, Stephan ^b   Aronow, Wilbert S ^c   Ahmed, Mustafa I ^d   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Biomarkers; Dilated cardiomyopathy; Heart failure; Therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CYSTATIN C; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SYNDECAN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EXAMINATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; EXERCISE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE; HEART TRANSPLANTATION; HEMOSTASIS; HOSPITAL READMISSION; HUMAN; KIDNEY FUNCTION; LEFT VENTRICULAR DIASTOLIC DIAMETER; LEFT VENTRICULAR SYSTOLIC DIAMETER; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPAIR; OBESITY; PREDICTION; PRIORITY JOURNAL; RIGHT VENTRICULAR DIASTOLIC DIAMETER; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REPAIR; UNDERWEIGHT; AGED; BLOOD; COMPLICATION; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84885670488     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.157     Document Type: Article

References (41)

1. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC 2012
2. WRITING GROUP MEMBERS, D. Lloyd-Jones, and R.J. Adams Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
3. S. Stewart, A. Jenkins, S. Buchan, A. McGuire, S. Capewell, and J.J. McMurray The current cost of heart failure to the National Health Service in the UK Eur J Heart Fail 4 2002 361 371
4. J. Remes, H. Miettinen, A. Reunanen, and K. Pyorala Validity of clinical diagnosis of heart failure in primary health care Eur Heart J 12 1991 315 321
5. N.M. Wheeldon, T.M. MacDonald, C.J. Flucker, A.D. McKendrick, D.G. McDevitt, and A.D. Struthers Echocardiography in chronic heart failure in the community Q J Med 86 1993 17 23
6. K. Dickens, A. Cohen-Solal, and G. Filippatos ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology Eur J Heart Fail 10 2008 933 989
7. P.F. Kantor, P. Rusconi, S. Lipshultz, S. Mital, J.D. Wilkinson, and M. Burch Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: summary from the Second International Conference On Pediatric Cardiomyopathy Prog Pediatr Cardiol 32 2011 11 14
8. E. Braunwald Biomarkers in heart failure N Engl J Med 358 2008 2148 2159
9. A.M. Kapoun, F. Liang, and G. O'Young B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation Circ Res 94 2004 453 461
10. A.S. Maisel, P. Krishnaswamy, and R.M. Nowak Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
11. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
12. J.A. de Lemos, D.K. McGuire, and M.H. Drazner B-type natriuretic peptide in cardiovascular disease Lancet 362 2003 316 322
13. D. Karasek, W. Sinkiewicz, and J. Błazejewski Relationship between B-type natriuretic peptide serum level, echocardiographic TEI index and the degree of diastolic dysfunction in patients with heart failure with preserved systolic function Arch Med Sci 7 2011 449 456
14. A. Bielecka-Dabrowa, J.H. Goch, and J. Rysz Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study Lipids Health Dis 9 Feb. 23 2010 21
15. K. Alagiakrishnan, M. Banach, L.G. Jones, S. Datta, A. Ahmed, and W.S. Aronow Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults Ann Med 45 2013 37 50
16. P. Elliott, B. Andersson, and E. Arbustini Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases Eur Heart J 29 2008 270 276
17. H. Faigenbaum, W.F. Armstrong, and T. Ryan Echokardiografia Faigenbauma Wydanie polskie 2006 Medipage Warszawa 238 239 [in Polish]
18. Drozdz J, Kopff A, Kasprzak JD. Echokardiografia dopplerowska. W: Hoffman P, Kasprzak JD (eds.). Echokardiografia. Gdańsk: wydanie I poprawione. 2005;23-29 (in Polish).
19. G.S. Bargiggia, C. Bertucci, and F. Recusani A new method for estimating left ventricular dP/dT by continuous wale Doppler-echocardiography. Validation studies at cardiac catheterization Circulation 80 1989 1287 1292
20. J.H. Brown, D.P. Del Re, and M.A. Sussman The Rac and Rho hall of fame: a decade of hypertrophic signaling hits Circ Res 98 2006 730 742
21. D.A. Morrow, and J.A. de Lemos Benchmarks for the assessment of novel cardiovascular biomarkers Circulation 115 8 2007 949 952
22. G. Wess, V. Butz, M. Mahling, and K. Hartmann Evaluation of N-terminal pro-B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers Am J Vet Res 72 5 2011 642 649
23. M. Prastaro, S. Paolillo, and G. Savarese N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction Eur J Echocardiogr 12 2011 506 513
24. M. Piechota, M. Banach, A. Jacoń, and J. Rysz Natriuretic peptides in cardiovascular diseases Cell Mol Biol Lett 13 2008 155 181
25. A. Bielecka-Dabrowa, J.H. Goch, D.P. Mikhailidis, J. Rysz, M. Maciejewski, and M. Banach The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy Med Sci Monit 15 2009 MS12 MS23
26. I. Raymond, B.A. Groenning, and P.R. Hildebrandt The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population Heart 89 2003 745 751
27. A.V. Finsen, I.G. Lunde, and I. Sjaastad Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway PLoS One 6 12 2011 e28302
28. R. Takahashi, K. Negishi, and A. Watanabe Serum syndecan-4 is a novel biomarker for patients with chronic heart failure J Cardiol 57 2011 325 332
29. Y. Matsui, M. Ikesue, and K. Danzaki Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction Circ Res 27 108 2011 1328 1339
30. N.G. Frangogiannis The immune system and cardiac repair Pharmacol Res 58 2008 88 111
31. D. Hilfiker-Kleiner, P. Shukla, and G. Klein Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction Circulation 122 2010 145 155
32. V. Kandalam, R. Basu, and T. Abraham Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction Am J Physiol Heart Circ Physiol 299 2010 H1012 H1023
33. L.A. Inker, and A. Okparavero Cystatin C as a marker of glomerular filtration rate: prospects and limitations Curr Opin Nephrol Hypertens 20 2011 631 639
34. M.G. Shipak, M.J. Sarnak, and R. Katz Cystatin C and mortality in elderly persons with heart failure J Am Coll Cardiol 45 2005 268 271
35. B. Franczyk-Skóra, A. Gluba, M. Banach, D. Kozłowski, J. Małyszko, and J. Rysz Prevention of sudden cardiac death in patients with chronic kidney disease BMC Nephrol 13 Dec. 3 2012 162
36. S. Manzano-Fernández, M. Boronat-Garcia, and M.D. Albaladejo-Otón Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure Am J Cardiol 103 2009 1753 1759
37. C. Gao, L. Zhong, Y. Gao, X. Li, M. Zhang, and S. Wei Cystatin C levels are associated with the prognosis of systolic heart failure patients Arch Cardiovasc Dis 104 2011 565 571
38. K. Damman, P. van der Harst, and T.D. Smilde Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure Heart 98 2012 319 324
39. A. Bielecka-Dabrowa, D.P. Mikhailidis, S. Hannam, W.S. Aronow, J. Rysz, and M. Banach Statins and dilated cardiomyopathy: do we have enough data? Expert Opin Investig Drugs 20 2011 315 323
40. O. Trojnarska, A. Gwizdała, and S. Katarzyński Evaluation of exercise capacity with cardiopulmonary exercise testing and BNP levels in adult patients with single or systemic right ventricles Arch Med Sci 6 2010 192 197
41. A. Gluba, A. Bielecka, and D.P. Mikhailidis An update on biomarkers of heart failure in hypertensive patients J Hypertens 30 2012 1681 1689